Quarterly report pursuant to Section 13 or 15(d)

Segments (Tables)

v3.19.1
Segments (Tables)
3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2019
 
2018
Revenue from services:
 
 
 
Pharmaceutical
$

 
$

Diagnostics
178,891

 
211,315

Corporate

 

 
$
178,891

 
$
211,315

Revenue from products:
 
 
 
Pharmaceutical
$
25,301

 
$
27,851

Diagnostics

 

Corporate

 

 
$
25,301

 
$
27,851

Revenue from transfer of intellectual property and other:
 
 
 
Pharmaceutical
$
18,259

 
$
15,748

Diagnostics

 

Corporate

 

 
$
18,259

 
$
15,748

Operating loss:
 
 
 
Pharmaceutical
$
(29,477
)
 
$
(22,948
)
Diagnostics
(33,569
)
 
(8,018
)
Corporate
(12,272
)
 
(11,645
)
 
$
(75,318
)
 
$
(42,611
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
7,526

 
$
6,740

Diagnostics
16,271

 
17,987

Corporate
19

 
30

 
$
23,816

 
$
24,757

Loss from investment in investees:
 
 
 
Pharmaceutical
$
(1,854
)
 
$
(2,172
)
Diagnostics

 
(284
)
Corporate

 

 
$
(1,854
)
 
$
(2,456
)
Revenues:
 
 
 
United States
$
184,894

 
$
215,311

Ireland
20,534

 
17,282

Chile
7,865

 
11,733

Spain
4,418

 
5,532

Israel
3,116

 
3,614

Mexico
1,531

 
1,420

Other
93

 
22

 
$
222,451

 
$
254,914


(In thousands)
March 31,
2019
 
December 31,
2018
Assets:
 
 
 
Pharmaceutical
$
1,230,811

 
$
1,236,499

Diagnostics
1,165,784

 
1,162,160

Corporate
178,706

 
52,413

 
$
2,575,301

 
$
2,451,072

Goodwill:

 

Pharmaceutical
$
245,735

 
$
247,407

Diagnostics
452,787

 
452,786

Corporate

 

 
$
698,522

 
$
700,193